E50

```
     FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007
L1          3011 S GALACTOMANNAN
L2         10748 S GUAR
L3        817398 S CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDI
L4            72 S L1 AND L3
L5           169 S L2 AND L3
L6            15 S L1 AND L2 AND L3
L7            40 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L8           112 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L9            12 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10        53680 S INTERLEUKIN(W)(2 OR 12)
L11         4527 S ALPHA-INTERFERON
L12            4 S L1 AND L10
L13            7 S L2 AND L10

     FILE 'STNGUIDE' ENTERED AT 12:47:04 ON 14 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 12:48:06 ON 14 AUG 2007
L14            4 S L12 AND (PY<2004 OR AY<2004 OR PRY<2004)
L15            5 S L13 AND (PY<2004 OR AY<2004 OR PRY<2004)
L16            2 S L14 AND L15
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.63       0.63

FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Aug 2007  VOL 147 ISS 8
FILE LAST UPDATED: 13 Aug 2007  (20070813/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s galactomannan

L1         3011 GALACTOMANNAN

=> s guar

L2        10748 GUAR

=> s cancer or tumor or neoplas? or fluorouracil or fluoropyrimidine or
fluorodeoxyuridine or chemotherap?

         325472 CANCER
         417600 TUMOR
         505396 NEOPLAS?
          19840 FLUOROURACIL
           1278 FLUOROPYRIMIDINE
           1906 FLUORODEOXYURIDINE
          94250 CHEMOTHERAP?
L3       817398 CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDINE
                OR FLUORODEOXYURIDINE OR CHEMOTHERAP?

=> s l1 and l3

L4           72 L1 AND L3

=> s l2 and l3

L5          169 L2 AND L3

=> s l1 and l2 and l3

L6           15 L1 AND L2 AND L3

=> s l4 and (PY<2004 or AY<2004 or PRY<2004)
```

```
      23927690 PY<2004
       4731693 AY<2004
       4213609 PRY<2004
L7          40 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l5 and (PY<2004 or AY<2004 or PRY<2004)

      23927690 PY<2004
       4731693 AY<2004
       4213609 PRY<2004
L8         112 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l6 and (PY<2004 or AY<2004 or PRY<2004)

      23927690 PY<2004
       4731693 AY<2004
       4213609 PRY<2004
L9          12 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> flie stnguide

FLIE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l9 1-12 ti abs bib

L9   ANSWER 1 OF 12  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Use of isomalt (mixture of 1,6-GPS and 1,1-GPM) as a prebiotic for the
     production of food and feed additives and medicaments used for the
     treatment of intestinal diseases, among other things
AB   The invention relates to a novel use of a mixture of 6-O-α-D-
     glucopyranosyl-D-sorbitol (1,6-GPS) and 1-O-α-D-glucopyranosyl-D-
     mannitol (1,1-GPM) as a bifidogenic prebiotic optionally containing a
     probiotic, to be used as or for producing a food item, semi-luxury food,
     fodder, or a medicament.  Said medicament is used for the treatment and/or
     prevention of intestinal diseases such as chronic inflammatory intestinal
     diseases, intestinal cancer, bacterial intestinal infections,
     among other things.
AN   2004:1154570  HCAPLUS <<LOGINID::20070814>>
DN   142:73725
TI   Use of isomalt (mixture of 1,6-GPS and 1,1-GPM) as a prebiotic for the
     production of food and feed additives and medicaments used for the
     treatment of intestinal diseases, among other things
IN   Klingeberg, Michael; Kozianowski, Gunhild; Kunz, Markwart; Theis, Stephan
PA   Suedzucker Aktiengesellschaft Mannheim/ochsenfurt, Germany
SO   PCT Int. Appl., 55 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2004112505        A1    20041229    WO 2004-EP6030         20040604 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
```

```
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
     DE 10328180          A1    20050113    DE 2003-10328180       20030616 <--
     AU 2004248895        A1    20041229    AU 2004-248895         20040604 <--
     CA 2527765           A1    20041229    CA 2004-2527765        20040604 <--
     EP 1641354           A1    20060405    EP 2004-739586         20040604 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1802101           A     20060712    CN 2004-80016063       20040604 <--
     BR 2004011528        A     20060801    BR 2004-11528          20040604 <--
     JP 2006527586        T     20061207    JP 2006-515829         20040604 <--
     MX 2005PA13815       A     20060313    MX 2005-PA13815        20051216 <--
     NO 2006000185        A     20060315    NO 2006-185            20060111 <--
     US 2006147500        A1    20060706    US 2006-561122         20060202 <--
PRAI DE 2003-10328180     A     20030616  <--
     WO 2004-EP6030       W     20040604
RE.CNT  4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 2 OF 12  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Improved thickened beverages for dysphagia
AB   The present invention relates to thickened beverage compns.  More
     particularly the invention relates to beverage compns. thickened for the
     management of dysphagia.  More particularly this invention relates to the
     production of thickened beverages by a dispensing machine that is also capable
     of dispensing non-thickened beverages.  The thickened beverages containing
     soluble food fiber thickener, especially xanthan gum, allows patients with
     swallowing difficulty to successfully swallow the beverages.
AN   2004:681524  HCAPLUS <<LOGINID::20070814>>
DN   141:195323
TI   Improved thickened beverages for dysphagia
IN   Holahan, John L.
PA   Simply Thick LLC, USA
SO   PCT Int. Appl., 36 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   WO 2004069179        A2     20040819    WO 2004-US2795         20040131 <--
     WO 2004069179        A3     20050714
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2004209974        A1     20040819    AU 2004-209974         20040131 <--
     CA 2509715           A1     20040819    CA 2004-2509715        20040131 <--
     EP 1590004           A2     20051102    EP 2004-707165         20040131 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006516995        T      20060713    JP 2006-503223         20040131 <--
     US 2006051296        A1     20060309    US 2005-542506         20050715 <--
PRAI US 2003-443941P      P      20030131  <--
     US 2003-444079P      P      20030131  <--
     US 2003-444080P      P      20030131  <--
     US 2003-444082P      P      20030131  <--
     WO 2004-US2795       W      20040131

L9   ANSWER 3 OF 12  HCAPLUS  COPYRIGHT 2007 ACS on STN
```

TI Coating technique for deposition of drug substance on a substrate
AB The present invention relates to a multi-layered, physiol. tolerated oral dosage form for pharmaceuticals. The dosage form comprises a central core, a middle layer, and an outer shell, at least one of which includes at least one pharmaceutical. By varying the diameter of the core, a different middle layer volume is obtained within a fixed outer shell dimension. This gives the ability to obtain different dosage strengths for one composition without the need of reformulation work. The oral dosage form is produced in a single-step, continuous process by coating the core with the middle layer and the outer shell. Tablets were prepared containing a core, an overlay, and a shell. The overlay and the shell were PEG-200 and Eudragit E100, resp. The core was a strand of poly(vinylidene fluoride).
AN 2003:851103 HCAPLUS <<LOGINID::20070814>>
DN 139:341755
TI Coating technique for deposition of drug substance on a substrate
IN Verreck, Geert; Rosenblatt, Joel; Liland, Alfred
PA Ethicon, Inc., USA
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1356808	A2	20031029	EP 2003-252647	20030425 <--
	EP 1356808	A3	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2003203027	A1	20031030	US 2002-134305	20020426 <--
	JP 2004035547	A	20040205	JP 2003-122484	20030425 <--
	US 2005158385	A1	20050721	US 2005-77680	20050311 <--
PRAI	US 2002-134305	A	20020426 <--		

L9 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Malleable protein matrix and uses thereof
AB The present invention relates to a malleable protein matrix (MPM) which is the reaction product of the agglomeration of proteins after a fermentation process, exhibits biol. activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophilic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its uses in food, drug, medical and cosmetic products.
AN 2003:511049 HCAPLUS <<LOGINID::20070814>>
DN 139:84363
TI Malleable protein matrix and uses thereof
IN Simard, Eric; Pilote, Dominique; Dupont, Claude; Lajoie, Nathalie; Paquet, Marcel; Lemieux, Pierre; Goyette, Philippe
PA Technologies Biolactis Inc., Can.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053158	A2	20030703	WO 2002-CA1988	20021220 <--
	WO 2003053158	A3	20030828		
	WO 2003053158	A9	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2470776	A1	20030703	CA 2002-2470776	20021220 <--
AU	2002351606	A1	20030709	AU 2002-351606	20021220 <--
EP	1458247	A2	20040922	EP 2002-787279	20021220 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP	2005513076	T	20050512	JP 2003-553926	20021220 <--
US	2006057131	A1	20060316	US 2005-499313	20050224 <--
PRAI US	2001-341232P	P	20011220 <--		
WO	2002-CA1988	W	20021220 <--		

L9 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for the treatment of wounds. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were mixed for 2 h. The penicillin solution was then added to an aqueous solution of TEMED and after thorough mixing, ammonium persulfate in water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Prior to testing, the sheets were placed in a humidified environment until the sheet weight had increased to approx. 118-122% the storage weight Disks were cut and placed onto the surfaces of agar plates that had previously been seeded with various strains of microorganisms (Staphylococcus aureus; Escherichia coli; Candida albicans; Pseudomonas aeruginosa). Zones of inhibition were measured around the penicillin containing matrix but not the control matrix on the S. aureus, E. coli, and P. aeruginosa plates. The results demonstrated the release of active penicillin G after its incorporation into the matrix.

AN 2002:182217 HCAPLUS <<LOGINID::20070814>>

DN 136:236843

TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

IN Gibbins, Bruce L.

PA AcryMed, Inc., USA

SO U.S., 14 pp., Cont.-in-part of U.S. 5,928,174.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355858	B1	20020312	US 1998-191223	19981113 <--
	US 6605751	B1	20030812	US 2000-675892	20000929 <--
	US 2004010215	A1	20040115	US 2003-441275	20030519 <--
	US 6897349	B2	20050524		
	US 2005226931	A1	20051013	US 2004-978556	20041101 <--
PRAI	US 1997-971074	A2	19971114 <--		
	US 1998-191223	A2	19981113 <--		
	US 1999-157000P	P	19991001 <--		
	US 2000-212455P	P	20000619 <--		
	US 2000-675892	A1	20000929 <--		

US 2003-441275 A1 20030519 <--
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Galactomannan Oligosaccharide and procedure for their production as well as their use
AB A process is provided for the manufacture of galactomannan derived oligosaccharides which can hinder infectious diseases, colon cancer, osteoporosis and stimulate the immune system. Thus, Bacillus subtilis cells immobilized in calcium alginate were employed to hydrolyze guar gum forming oligosaccharides with a d.p. less than 15 residues preferably between 2 and 7 residues. The resulting oligosaccharides were partially purified by ion exchange chromatog.
AN 2001:449805 HCAPLUS <<LOGINID::20070814>>
DN 135:45276
TI Galactomannan Oligosaccharide and procedure for their production as well as their use
IN Klingeberg, Michael; Kunz, Markwart; Ludwig, Eva; Munir, Mohammad; Rittig, Frank; Vogel, Manfred
PA Suedzucker Aktiengesellschaft Mannheim/Ochsenfurt, Germany
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19961182	A1	20010621	DE 1999-19961182	19991218 <--
	DE 19961182	B4	20060112		
	CA 2394640	A1	20010621	CA 2000-2394640	20001212 <--
	WO 2001044489	A2	20010621	WO 2000-EP12574	20001212 <--
	WO 2001044489	A3	20020214		
	W: AU, CA, IL, JP, KR, MX, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	EP 1303632	A2	20030423	EP 2000-991171	20001212 <--
	EP 1303632	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2003516757	T	20030520	JP 2001-545566	20001212 <--
	AT 278799	T	20041015	AT 2000-991171	20001212 <--
	AU 779681	B2	20050203	AU 2001-31575	20001212 <--
	PT 1303632	T	20050228	PT 2000-991171	20001212 <--
	ES 2228661	T3	20050416	ES 2000-991171	20001212 <--
	RU 2281331	C2	20060810	RU 2002-119059	20001212 <--
	MX 2002PA06044	A	20030128	MX 2002-PA6044	20020618 <--
	US 2003162300	A1	20030828	US 2002-168044	20021219 <--
PRAI	DE 1999-19961182	A	19991218 <--		
	WO 2000-EP12574	W	20001212 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
AB The present invention relates to a nutritional composition which contains slightly neg. charged non-digestible polysaccharides having a mol. weight of 8 kD to 40,000 kD, characterized in that the rise in the viscosity of the composition caused by the polysaccharides is less than 20 mPa.s. The invention also relates to the use of this nutritional composition to reduce the uptake of high mol. weight substances, allergens and microorganisms through the intestinal wall, more particularly to reduce transport of high mol. weight

substances, allergens and microorganisms through the tight junctions in the intestines. The nutritional compns. can be used to prevent or to treat allergies, allergic reactions, sepsis and inflammatory processes, such as those which can arise under emotional and phys. stress, ischemia, reperfusion damage during and after operations, following radiation treatment and/or chemotherapy of cancer patients and in the case of inflammatory intestinal diseases, diarrhea and allergies.

AN 2000:706937 HCAPLUS <<LOGINID::20070814>>

DN 133:265962

TI Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions

IN Bijlsma, Pieter Brandt; Groot, Jacques Alphons; Timmermans, Johannes Wilhelmus; Van Der Meulen, Jan; Kiliaan, Amanda Johanne

PA N.V. Nutricia, Neth.

SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000057727	A1	20001005	WO 2000-NL187	20000321 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	NL 1011680	C2	20000927	NL 1999-1011680	19990326 <--
	EP 1164874	A1	20020102	EP 2000-914366	20000321 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539809	T	20021126	JP 2000-607492	20000321 <--
	US 6686341	B1	20040203	US 2002-937395	20020102 <--
PRAI	NL 1999-1011680	A	19990326 <--		
	WO 2000-NL187	W	20000321 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Immunoglobulin production regulating activity of dietary fibers

AB In rats fed some types of dietary fat, class specific increases or decreases of serum Igs (Ig), changes in Ig productivity of spleen and mesenteric lymph node (MLN) lymphocytes, changes in T cell populations of splenocytes, and changes in cytokine productivity in MLN lymphocytes have been reported. In comparison with the water-insol. dietary fiber cellulose the soluble forms pectin, glucomannan and chitosan enhanced the production of IgA and IgG, but inhibit the production of IgE. The proportion of CD8 cells in rats fed these dietary fibers are significantly lower than rats fed cellulose and the proportion of CD4 cells is significantly elevated. In addition, production of interferon-γ and tissue necrosis factor-α by MLN lymphocytes is significantly enhanced by pectin as compared with cellulose. These results suggest that dietary fibers in the diet affect Ig production by influencing T cell differentiation and cytokine synthesis. Though similar Ig production regulating activity is observed galactomannan guar gum, enzymically degraded guar gum exerts lower activity. When MLN lymphocytes are cultured in the presence of glucomannan, galactomannan, or their structural sugars, no change in the Ig productivity has been observed These results suggest that the above effects are not due to the direct

interaction of dietary fibers or their metabolites on the Ig production system.
AN 2000:418862 HCAPLUS <<LOGINID::20070814>>
DN 133:281020
TI Immunoglobulin production regulating activity of dietary fibers
AU Yamada, Koji
CS Lab. Food Chem., Div. Bioresource Bioenvironmental Sci., Grad. Sch. Kyushu Univ., Fukuoka, 812-8581, Japan
SO Foods & Food Ingredients Journal of Japan (2000), 186, 26-32
CODEN: FFIJER; ISSN: 0919-9772
PB FFI Janaru
DT Journal
LA Japanese

L9 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
AB A colonic drug delivery composition contains a first polysaccharide and a second polysaccharide wherein both polysaccharides are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above. A colon selective pharmaceutical composition and dosage form for oral delivery of a drug, nutrient, diagnostic reagent, or mixture thereof includes the drug, nutrient, diagnostic reagent, or mixture thereof in contact with the polysaccharide composition A method of preparing such a colonic drug delivery composition and the colon selective pharmaceutical composition and dosage form are also disclosed. Capsules filled with budesonide pellets were coated with a composition containing pectin and guar gum at the ratio of 4 to 1 (pH 8), to a thickness of 15 mg/cm2. The capsules were disintegrated in 60 min in simulated colonic fluid, but not disintegrated in simulated gastric or intestinal fluid during 24 h studies.
AN 2000:68148 HCAPLUS <<LOGINID::20070814>>
DN 132:113102
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
IN Lee, Seung Seo; Lim, Chang Baeg; Pai, Chaul Min; Lee, Sujung; Park, In; Seo, Moon Gun; Park, Heenam
PA Samyang Corporation, S. Korea
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 974344	A2	20000126	EP 1999-305600	19990715 <--
	EP 974344	A3	20000301		
	EP 974344	B1	20040303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	KR 2000011247	A	20000225	KR 1999-14665	19990423 <--
	CA 2336815	A1	20000203	CA 1999-2336815	19990520 <--
	CA 2336815	C	20050607		
	WO 2000004924	A1	20000203	WO 1999-KR250	19990520 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9940627	A	20000214	AU 1999-40627	19990520 <--
	AU 744183	B2	20020214		
	JP 2002521346	T	20020716	JP 2000-560917	19990520 <--

	US 6413494	B1	20020702	US 1999-318579	19990525 <--
	AT 260649	T	20040315	AT 1999-305600	19990715 <--
	ES 2214813	T3	20040916	ES 1999-305600	19990715 <--
	KR 2001074641	A	20010804	KR 2001-700082	20010104 <--
	MX 2001PA00768	A	20020408	MX 2001-PA768	20010122 <--
PRAI	KR 1998-29740	A	19980723 <--		
	KR 1999-14665	A	19990423 <--		
	WO 1999-KR250	W	19990520 <--		

L9 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Improved wound dressing device and methods
AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of wounds. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg guar gum was dispersed in a mixture containing 0.9770 kg isopropanol and 2 kg water. The solution of guar gum was dispersed into the acrylamide mixture After suitable mixing, 0.1042 kg TEMED was added and polymerization was catalyzed with 0.0999 kg ammonium persulfate. While the batch was still liquid, it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.
AN 1999:350613 HCAPLUS <<LOGINID::20070814>>
DN 130:357215
TI Improved wound dressing device and methods
IN Gibbins, Bruce L.
PA USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925395	A2	19990527	WO 1998-US24272	19981113 <--
	WO 9925395	A3	19990812		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9916991	A	19990607	AU 1999-16991	19981113 <--
	EP 1030695	A2	20000830	EP 1998-961733	19981113 <--
	EP 1030695	B1	20050406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 292481	T	20050415	AT 1998-961733	19981113 <--
PRAI	US 1997-971074	A2	19971114 <--		
	WO 1998-US24272	W	19981113 <--		

L9 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI β-Glucuronidase-inhibiting compositions containing low-molecular weight galactomannan
AB The title compns., useful for prevention of colon cancer, contain low-mol. weight galactomannan, ≥80% of which is linear chains of 30-200 mannose units. A drink containing low-mol.-weight

galactomannan (manufactured from guar gum with β-mannase) was ingested by volunteers to show less formation of β-glucuronidase by intestinal bacteria.

AN 1995:235235 HCAPLUS <<LOGINID::20070814>>
DN 122:8814
TI β-Glucuronidase-inhibiting compositions containing low-molecular weight galactomannan
IN Ishihara, Noryuki; Ookubo, Tsutomu
PA Taiyo Kagaku Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06256196	A	19940913	JP 1993-67497	19930302 <--
	JP 3801658	B2	20060726		
PRAI	JP 1993-67497		19930302 <--		

L9 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO4, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing nifedipine with micronized crosslinked PVP (1:5) 240, BaSO4 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.
AN 1993:154582 HCAPLUS <<LOGINID::20070814>>
DN 118:154582
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
IN Esposito, Pierandrea; Carli, Fabio
PA Vectorpharma International S.p.A., Italy
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803 <--
	EP 526862	B1	19960214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 134134	T	19960215	AT 1992-113187	19920803 <--
	ES 2086029	T3	19960616	ES 1992-113187	19920803 <--
PRAI	IT 1991-MI2212	A	19910806 <--		

=> d his

(FILE 'HOME' ENTERED AT 11:36:11 ON 14 AUG 2007)

FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007

L1	3011	S	GALACTOMANNAN
L2	10748	S	GUAR
L3	817398	S	CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDI
L4	72	S	L1 AND L3
L5	169	S	L2 AND L3
L6	15	S	L1 AND L2 AND L3
L7	40	S	L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L8	112	S	L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

```
L9            12 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    36.56      37.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.36      -9.36

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:38:42 ON 14 AUG 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 12:45:33 ON 14 AUG 2007
FILE 'HCAPLUS' ENTERED AT 12:45:33 ON 14 AUG 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    36.56      37.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.36      -9.36

=> s interleukin(w)(2 or 12)
        163794 INTERLEUKIN
       9254807 2
       1485332 12
L10      53680 INTERLEUKIN(W)(2 OR 12)

=> s alpha-interferon

       1703981 ALPHA
         78349 INTERFERON
L11       4527 ALPHA-INTERFERON
                 (ALPHA(W)INTERFERON)

=> s l1 and l10

L12           4 L1 AND L10

=> s l2 and l10

L13           7 L2 AND L10

=> file stnguide

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    44.36      44.99
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -9.36      -9.36

FILE 'STNGUIDE' ENTERED AT 12:47:04 ON 14 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 10, 2007 (20070810/UP).

=> file hcaplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.12      45.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -9.36

FILE 'HCAPLUS' ENTERED AT 12:48:06 ON 14 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Aug 2007  VOL 147 ISS 8
FILE LAST UPDATED: 13 Aug 2007  (20070813/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> S L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

      23927690 PY<2004
       4731693 AY<2004
       4213609 PRY<2004
L14           4 L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> S L13 AND (PY<2004 OR AY<2004 OR PRY<2004)

      23927690 PY<2004
       4731693 AY<2004
       4213609 PRY<2004
L15           5 L13 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l14 and l15

L16           2 L14 AND L15

=> file stnguide
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	47.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'STNGUIDE' ENTERED AT 12:48:13 ON 14 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 10, 2007 (20070810/UP).

=> d l16 1-2 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal
AB Disclosed are novel methods that generally rely on immunization against autologous ghrelin. Immunization is preferably effected by administration of analogs of autologous ghrelin, said analogs being capable of inducing antibody production against the autologous ghrelin polypeptides. Especially preferred as an immunogen is autologous ghrelin, which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against ghrelin and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
AN 2004:252369 HCAPLUS <<LOGINID::20070814>>
DN 140:269531
TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal
IN Boving, Tine Elisabeth Gottschalk; Klysner, Steen
PA Pharmexa A/s, Den.
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024183	A1	20040325	WO 2003-DK592	20030912 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498739	A1	20040325	CA 2003-2498739	20030912 <--
AU 2003263150	A1	20040430	AU 2003-263150	20030912 <--
EP 1539232	A1	20050615	EP 2003-794825	20030912 <--

```
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1694724            A     20051109    CN 2003-825086          20030912 <--
     JP 2006504413         T     20060209    JP 2004-535024          20030912 <--
     MX 2005PA02699        A     20050920    MX 2005-PA2699          20050310 <--
     IN 2005KN00485        A     20060623    IN 2005-KN485           20050323 <--
     NO 2005001779         A     20050411    NO 2005-1779            20050411 <--
     ZA 2005002929         A     20060222    ZA 2005-2929            20050411 <--
PRAI DK 2002-1345          A     20020912  <--
     US 2002-410164P       P     20020912  <--
     WO 2003-DK592         W     20030912  <--
RE.CNT  7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16  ANSWER 2 OF 2  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Silver-containing compositions, devices and methods for making them
AB   The present invention comprises methods and compns. for making a
     silver-containing antimicrobial hydrophilic material.  More particularly, the
     present invention comprises methods and compns. for stabilized silver
     antimicrobial devices comprising a matrix comprising a polymer network and
     a non-gelable polysaccharide, and an active agent.  The matrix may be
     formed into any desired shape for its desired uses.
AN   2001:265285  HCAPLUS <<LOGINID::20070814>>
DN   134:300843
TI   Silver-containing compositions, devices and methods for making them
IN   Gibbins, Bruce L.; Hopman, Lance D.
PA   Acrymed, USA
SO   PCT Int. Appl., 63 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
PI   WO 2001024839          A1     20010412    WO 2000-US26890         20000929 <--
     WO 2001024839          A9     20021114
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1216065             A1     20020626    EP 2000-970522          20000929 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
PRAI US 1999-157000P       P      19991001  <--
     US 2000-212455P       P      20000619  <--
     WO 2000-US26890       W      20000929  <--
RE.CNT  8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l15 1-5 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L15  ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Nonsteroidal immunomodulating kit and composition and uses thereof

L15  ANSWER 2 OF 5  HCAPLUS  COPYRIGHT 2007 ACS on STN
```

TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal

L15 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nanoparticulate compositions of angiogenesis inhibitors

L15 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Silver-containing compositions, devices and methods for making them

L15 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

=> d l15 1 3 5 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nonsteroidal immunomodulating kit and composition and uses thereof
AB A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including: a) a container accommodating a pressurized product; and b) an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a nonsteroidal immunomodulating agent; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixts. thereof, at a concentration of about 2%
to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alc., a fatty acid, a hydroxy fatty acid; and mixts. thereof; v. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; vi. water; and vii. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
AN 2005:1132617 HCAPLUS <<LOGINID::20070814>>
DN 143:393082
TI Nonsteroidal immunomodulating kit and composition and uses thereof
IN Tamarkin, Dov; Eini, Meir; Friedman, Doron
PA Foamix Ltd., Israel
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 911,367.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005232869	A1	20051020	US 2005-78902	20050311 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005069566 A1 20050331 US 2004-911367 20040804 <--

WO 2007007208 A2 20070118 WO 2006-IB2755 20060310

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI IL 2002-152486 A 20021025 <--

US 2002-429546P P 20021129 <--

US 2003-492385P P 20030804 <--

WO 2003-IB5527 A2 20031024 <--

US 2004-911367 A2 20040804

US 2005-78902 A 20050311

L15 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nanoparticulate compositions of angiogenesis inhibitors

AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compns. have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compns. For example, a nanoparticulate dispersion was prepared by milling a mixture containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% < 144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°, the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle size of 195 nm.

AN 2003:777565 HCAPLUS <<LOGINID::20070814>>

DN 139:296972

TI Nanoparticulate compositions of angiogenesis inhibitors

IN Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt, John; Ryde, Tuula; Jain, Rajeev; Walters, Amy

PA Elan Pharma International Ltd., USA

SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003080027	A1	20031002	WO 2003-US8546	20030320 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2479665	A1	20031002	CA 2003-2479665	20030320 <--
AU 2003230691	A1	20031008	AU 2003-230691	20030320 <--
US 2004033267	A1	20040219	US 2003-392403	20030320 <--
EP 1490030	A1	20041229	EP 2003-723781	20030320 <--

```
     EP 1490030            B1    20061025
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005530712         T     20051013    JP 2003-577857          20030320 <--
     AT 343376             T     20061115    AT 2003-723781          20030320 <--
     EP 1800666            A1    20070627    EP 2006-22201           20030320 <--
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
PRAI US 2002-365540P      P     20020320  <--
     US 2002-366542P      P     20020325  <--
     EP 2003-723781       A3    20030320  <--
     WO 2003-US8546       W     20030320  <--
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15  ANSWER 5 OF 5  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Gas and gaseous precursor filled microspheres as topical and subcutaneous
     delivery vehicles
AB   Gas and gaseous precursor filled microspheres, and foams provide novel
     topical and s.c. delivery vehicles for various active ingredients,
     including drugs and cosmetics.  Gas and gaseous precursor filled
     microcapsules were prepared from dipalmitoylphosphatidylcholine.
AN   1998:207280  HCAPLUS <<LOGINID::20070814>>
DN   128:275101
TI   Gas and gaseous precursor filled microspheres as topical and subcutaneous
     delivery vehicles
IN   Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David
PA   Imarx Pharmaceutical Corp., USA
SO   U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 21
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
PI   US 5733572             A     19980331    US 1994-346426          19941129 <--
     US 5088499             A     19920218    US 1990-569828          19900820 <--
     WO 9109629             A1    19910711    WO 1990-US7500          19901219 <--
         W:  CA, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
     JP 05502675            T     19930513    JP 1991-503276          19901219 <--
     JP 3309356             B2    20020729
     AT 180170              T     19990615    AT 1991-902857          19901219 <--
     ES 2131051             T3    19990716    ES 1991-902857          19901219 <--
     CA 2069759             C     20070116    CA 1990-2069759         19901219 <--
     US 5228446             A     19930720    US 1991-717084          19910618 <--
     WO 9222247             A1    19921223    WO 1992-US2615          19920331 <--
         W:  AU, CA, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE
     AU 9220020             A     19930112    AU 1992-20020           19920331 <--
     AU 667471              B2    19960328
     JP 06508364            T     19940922    JP 1993-500847          19920331 <--
     JP 3456584             B2    20031014
     EP 616508              A1    19940928    EP 1992-912456          19920331 <--
     EP 616508              B1    20010718
     EP 616508              B2    20040929
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
     AT 203148              T     20010815    AT 1992-912456          19920331 <--
     ES 2159280             T3    20011001    ES 1992-912456          19920331 <--
     CA 2110491             C     20070724    CA 1992-2110491         19920331 <--
     US 5469854             A     19951128    US 1993-76239           19930611 <--
     US 5580575             A     19961203    US 1993-76250           19930611 <--
     US 5348016             A     19940920    US 1993-88268           19930707 <--
     US 5542935             A     19960806    US 1993-160232          19931130 <--
```

```
     US 5585112           A     19961217    US 1993-159687          19931130 <--
     US 5769080           A     19980623    US 1994-199462          19940222 <--
     WO 9428874           A1    19941222    WO 1994-US5633          19940519 <--
         W:  AU, CA, CN, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     US 5773024           A     19980630    US 1994-307305          19940916 <--
     CA 2177713           A1    19950608    CA 1994-2177713         19941130 <--
     WO 9515118           A1    19950608    WO 1994-US13817         19941130 <--
         W:  AU, CA, CN, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     EP 740528            A1    19961106    EP 1995-908414          19941130 <--
     EP 740528            B1    20030326
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     JP 09506098          T     19970617    JP 1995-515763          19941130 <--
     AT 235228            T     20030415    AT 1995-908414          19941130 <--
     US 5571497           A     19961105    US 1995-468056          19950606 <--
     CN 1180310           A     19980429    CN 1996-193069          19960327 <--
     CN 1102045           B     20030226
     US 6001335           A     19991214    US 1996-665719          19960618 <--
     US 5935553           A     19990810    US 1996-758179          19961125 <--
     US 6743779           B1    20040601    US 1997-841169          19970429 <--
     US 5985246           A     19991116    US 1997-888426          19970708 <--
     AU 9856271           A     19980507    AU 1998-56271           19980224 <--
     AU 713127            B2    19991125
     AU 9888405           A     19981203    AU 1998-88405           19981012 <--
     AU 731072            B2    20010322
     HK 1013625           A1    20000420    HK 1998-114978          19981223 <--
     AU 9910043           A     19990304    AU 1999-10043           19990104 <--
     GR 3036877           T3    20020131    GR 2001-401740          20011011 <--
PRAI US 1989-455707       B2    19891222  <--
     US 1990-569828       A2    19900820  <--
     US 1991-716899       B2    19910618  <--
     US 1991-717084       A2    19910618  <--
     US 1993-76239        A2    19930611  <--
     US 1993-76250        A2    19930611  <--
     US 1993-159674       B2    19931130  <--
     US 1993-159687       A2    19931130  <--
     US 1993-160232       A2    19931130  <--
     US 1994-307305       A2    19940916  <--
     WO 1990-US7500       W     19901219  <--
     US 1991-716793       A     19910618  <--
     US 1991-750877       A3    19910826  <--
     US 1992-818069       A3    19920108  <--
     WO 1992-US2615       A     19920331  <--
     US 1992-967974       A3    19921027  <--
     US 1993-17683        A3    19930212  <--
     US 1993-18112        B3    19930217  <--
     US 1993-85608        A3    19930630  <--
     US 1993-88268        A3    19930707  <--
     US 1993-163039       A3    19931206  <--
     US 1994-212553       B2    19940311  <--
     AU 1994-70416        A3    19940519  <--
     US 1994-346426       A     19941129  <--
     AU 1995-21850        A3    19941130  <--
     WO 1994-US13817      W     19941130  <--
     US 1995-395683       A3    19950228  <--
     US 1995-468056       A3    19950606  <--
     US 1995-471250       A3    19950606  <--
     US 1996-640554       B2    19960501  <--
     US 1996-665719       A3    19960618  <--
     US 1997-785661       B2    19970117  <--
RE.CNT  314   THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```